SCHEMBL3883019

SCHEMBL3883019

COc1ccc2cc(-c3ccccc3)c(C(=O)C(=O)Cl)n2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
THRB P10828 1/20 0.44
GABRA1 P14867 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
BACE1 P56817 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
RECQL P46063 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HDAC8 Q9BY41 2/20 0.39
HTT P42858 1/20 0.39
GFER P55789 1/20 0.39
GAA P10253 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4433574 0.88 SMN1; SMN2 (0.46) SMN1; SMN2THRBGABRA1GABRG2GABRB3
SCHEMBL3884848 0.83 SMN1; SMN2 (0.49) SMN1; SMN2THRBL3MBTL1ALDH1A1MAPT
SCHEMBL1643301 0.82 POLB (0.49) SMN1; SMN2THRBGABRA1GABRG2GABRB3
SCHEMBL1645639 0.80 SMN1; SMN2 (0.47) SMN1; SMN2THRBGABRA1GABRG2GABRB3
SCHEMBL3886901 0.78 CYP19A1 (0.45) SMN1; SMN2THRBL3MBTL1ALDH1A1MAPT
SCHEMBL1645179 0.78 MAPT (0.46) SMN1; SMN2THRBGABRA1GABRG2GABRB3
SCHEMBL1645731 0.77 SMN1; SMN2 (0.68) SMN1; SMN2THRBL3MBTL1ALDH1A1MAPT
SCHEMBL1646571 0.76 LMNA (0.45) SMN1; SMN2THRBALDH1A1MAPTMEN1
SCHEMBL7984046 0.75 USP2 (0.52) SMN1; SMN2L3MBTL1ALDH1A1POLB
SCHEMBL3885596 0.74 CYP19A1 (0.47) SMN1; SMN2THRBL3MBTL1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed
EP-1888063-A1 ANTIFUNGAL AGENTS F2G Ltd. (GB) 2008-02-20 EP disclosed
WO-2006123145-A1 ANTIFUNGAL AGENTS F2G LTD (GB) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 SMN1; SMN2 3501/4885THRB 2955/4885GABRA1 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.